Devonian Health Group Inc. (CVE:GSD – Get Free Report) shares fell 10.3% on Thursday . The company traded as low as C$10.00 and last traded at C$10.00. 1,800 shares traded hands during trading, an increase of 50% from the average session volume of 1,201 shares. The stock had previously closed at C$11.15.
Devonian Health Group Price Performance
The stock has a market capitalization of C$27.81 million, a P/E ratio of -2.88 and a beta of 0.46. The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The company’s 50-day simple moving average is C$11.12 and its 200-day simple moving average is C$11.78.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.
See Also
- Five stocks we like better than Devonian Health Group
- Microsoft Just Gave Investors 3 Dates They Can’t Afford to Ignore
- NVIDIA’s Outlook Gains Momentum: Stock Price to Follow
- The World Cup Is Coming—These 3 Stocks Could Cash In
- Spotify’s “North Star” Outlook Was Music to Investors Ears
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
